文献速递乳房整形与再造显微修复重建

机器人辅助淋巴静脉吻合术治疗乳腺癌相关淋巴水肿的首个人体试验一年结果

One-Year Outcomes of the First Human Trial on Robot-Assisted Lymphaticovenous Anastomosis for Breast Cancer-Related Lymphedema.
PubMed 文献 · Plast Reconstr Surg · 2022-01-01

前瞻性预试验将乳腺癌相关淋巴水肿女性随机分为机器人辅助或手动淋巴静脉吻合术组,共纳入20例(机器人组8例,手动组12例)。两组生活质量在12个月时均显著改善(机器人组p=0.045,手动组p=0.001),臂围未下降,吻合口通畅率总体76.5%(机器人组66.6%,手动组81.8%)。作者认为机器人辅助淋巴静脉吻合术可行,临床结局与手动相当。

要点

  • 机器人组8例与手动组12例在12个月时生活质量均显著改善,臂围均未下降。
  • 每日弹力衣使用频率机器人组下降61.9%,手动组下降70.2%。
  • 吻合口总体通畅率76.5%,机器人组66.6%,手动组81.8%。

核心结论

  • 作者认为,基于1年随访数据,本研究证实机器人辅助淋巴静脉吻合术的可行性,其临床结局与手动淋巴静脉吻合术相当。
  • 作者鼓励进一步研究使用新型显微外科机器人MUSA进行淋巴静脉吻合术及其他(超)显微外科手术。

研究设计与样本

  • 前瞻性预试验,将乳腺癌相关淋巴水肿女性随机分为机器人辅助或手动淋巴静脉吻合术组,共纳入20例,其中机器人组8例,手动组12例。
  • 证据等级为治疗性,II级。

主要发现

  • 12个月时,两组生活质量均显著改善(机器人组p=0.045,手动组p=0.001)。
  • 臂围未下降(机器人组p=0.094,手动组p=0.240)。
  • 每日弹力衣使用频率机器人组下降61.9%,手动组下降70.2%;手动淋巴引流频率与基线相比保持相似。
  • 臂部皮肤回流分期在机器人组1例和手动组5例中降低;吻合口总体通畅率76.5%,机器人组66.6%,手动组81.8%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphaticovenous anastomosis, a supermicrosurgical technique, creates bypasses between the lymphatic and venous systems. The quality of lymphaticovenous anastomosis depends on the surgeon's dexterity and precision, and is subject to imperfections caused by the physiologic tremor of the human hand. A dedicated robot for microsurgery has been created to overcome these limitations (MUSA, MicroSure, Eindhoven, The Netherlands). This study describes 1-year clinical outcomes of the first-in-human trial of robot-assisted and manual lymphaticovenous anastomosis in patients with breast cancer-related lymphedema. METHODS: In this prospective pilot study, women with breast cancer-related lymphedema were randomized into the robot-assisted or manual lymphaticovenous anastomosis group. Outcomes were quality of life, arm circumference, conservative treatment frequency, arm dermal backflow stage, and anastomosis patency. RESULTS: Twenty women were included, of whom eight underwent robot-assisted lymphaticovenous anastomosis surgery and 12 underwent manual surgery. In both groups, quality of life significantly improved at 12 months (robot-assisted surgery, p = 0.045; manual surgery, p = 0.001). Arm circumference did not decrease (robot-assisted surgery, p = 0.094; manual surgery, p = 0.240). Daily use of compression garments decreased by 61.9 percent (robot-assisted surgery) and 70.2 percent (manual surgery). The frequency of manual lymphatic drainage remained similar compared with baseline. Arm dermal backflow stage was reduced in one patient in the robot-assisted group and in five cases in the manual group. Overall, 76.5 percent of the anastomoses were patent (robot-assisted surgery, 66.6 percent; manual surgery, 81.8 percent). CONCLUSIONS: After evaluating 1-year follow-up data, this study confirms the feasibility of robot-assisted lymphaticovenous anastomosis surgery. Clinical outcomes were comparable between robot-assisted and manual lymphaticovenous anastomosis. This encourages further research using the new microsurgical robot MUSA for lymphaticovenous anastomosis and other (super)microsurgical procedures. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. van Mulken TJM, Wolfs JAGN, Qiu SS, et al. One-Year Outcomes of the First Human Trial on Robot-Assisted Lymphaticovenous Anastomosis for Breast Cancer-Related Lymphedema. Plast Reconstr Surg. 2022. PMID: 34936615. doi:10.1097/PRS.0000000000008670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。